We observed increased PD-L1 on tumor cells and increased PD-1 on T cells with DNMTi + HDAC6i and thus tested combination treatment with anti-PD-1, but this produced no benefit, perhaps because of the very high levels of PD-L1 ligand produced by the combination treatment. Here, PDCD1 is linked to neoplasm.